Cargando…
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy
The mammalian target of rapamycin (mTOR) is an intracellular serine/threonine protein kinase positioned at a central point in a variety of cellular signaling cascades. The established involvement of mTOR activity in the cellular processes that contribute to the development and progression of cancer...
Autores principales: | Yuan, RuiRong, Kay, Andrea, Berg, William J, Lebwohl, David |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2775749/ https://www.ncbi.nlm.nih.gov/pubmed/19860903 http://dx.doi.org/10.1186/1756-8722-2-45 |
Ejemplares similares
-
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019) -
MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors
por: Clegg, Nicola J., et al.
Publicado: (2011) -
Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021) -
mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016) -
Targeting mTOR for cancer therapy
por: Hua, Hui, et al.
Publicado: (2019)